Cencora Inc. (COR)

Working capital turnover

Dec 31, 2023 Sep 30, 2023 Jun 30, 2023 Mar 31, 2023 Dec 31, 2022 Sep 30, 2022 Jun 30, 2022 Mar 31, 2022 Dec 31, 2021 Sep 30, 2021 Jun 30, 2021 Mar 31, 2021 Dec 31, 2020 Sep 30, 2020 Jun 30, 2020 Mar 31, 2020 Dec 31, 2019 Sep 30, 2019 Jun 30, 2019 Mar 31, 2019
Revenue (ttm) US$ in thousands 271,579,300 262,173,300 254,425,100 247,542,700 241,804,900 238,586,900 236,325,200 229,666,300 221,101,100 213,988,900 204,321,300 196,282,400 194,545,800 189,893,900 186,286,900 186,159,400 182,061,400 179,589,200 177,248,500 175,151,500
Total current assets US$ in thousands 44,858,700 42,798,800 40,986,600 39,989,600 40,708,100 39,589,800 39,744,500 39,409,700 39,378,900 38,802,600 37,259,800 35,469,100 34,700,200 33,055,700 29,918,600 31,180,600 28,954,800 28,132,100 27,401,800 27,622,200
Total current liabilities US$ in thousands 50,773,500 48,831,200 46,783,200 45,071,100 44,760,600 43,478,000 43,154,300 42,797,600 41,613,600 41,358,600 39,589,800 32,996,400 35,044,500 33,853,100 30,631,600 32,111,800 30,630,500 29,581,300 28,788,900 29,211,900
Working capital turnover 79.38

December 31, 2023 calculation

Working capital turnover = Revenue (ttm) ÷ (Total current assets – Total current liabilities)
= $271,579,300K ÷ ($44,858,700K – $50,773,500K)
= —

As per the presented data, the working capital turnover ratio for Cencora Inc. is not available for the specified periods. Without this information, it is not possible to assess the efficiency of the company in utilizing its working capital to support sales and operations. To conduct a comprehensive analysis of Cencora Inc.'s working capital turnover, it would be necessary to have the relevant financial figures for the current assets and current liabilities. These would enable computation of the working capital turnover ratio, a key indicator of the company's management of its short-term assets and liabilities in relation to its revenue generation.


Peer comparison

Dec 31, 2023

Company name
Symbol
Working capital turnover
Cencora Inc.
COR
Cardinal Health Inc
CAH
McKesson Corporation
MCK
Nu Skin Enterprises Inc
NUS
5.21